首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

下一代癌症诊断市场规模、份额和成长分析（按产品/服务、技术、癌症类型、应用、最终用途和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1900127

下一代癌症诊断市场规模、份额和成长分析（按产品/服务、技术、癌症类型、应用、最终用途和地区划分）—2026-2033年产业预测

Next Generation Cancer Diagnostics Market Size, Share, and Growth Analysis, By Product and Services (Products, Services), By Technology, By Cancer Type, By Application, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计下一代癌症诊断市场规模在 2024 年将达到 188.4 亿美元，从 2025 年的 223.3 亿美元增长到 2033 年的 868.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 18.5%。

在创新诊断设备、试剂盒和试剂商业化的推动下，下一代癌症诊断市场正经历着快速就地检验(POCT) 的变革性转变。预计这一转变将推动市场成长，尤其是在伴随诊断兴起的情况下，伴随诊断对于提供先进的个人化基因组医学至关重要。全球各种癌症发生率的不断上升凸显了对先进诊断工具的需求，这些工具能够促进早期发现，从而改善治疗效果。随着新型生物标记的不断涌现，癌症诊断的准确性和成本效益也不断提高。对微创技术的关注进一步强调了早期发现对于实现积极患者预后的关键作用，有助于应对与癌症死亡率上升相关的重大医疗保健挑战。

下一代癌症诊断市场驱动因素

对个人化医疗日益增长的需求正显着推动下一代癌症诊断市场的扩张。这种方法着重为每位患者量身定制治疗方案，充分考虑其独特的基因组成和其他特征。该领域的先进诊断工具在识别最有可能对标靶治疗良好反应的患者方面发挥关键作用。随着越来越多的医疗专业人员认识到这些客製化治疗策略的益处，他们对创新诊断解决方案的依赖性日益增强，从而推动了市场成长，并最终改善了癌症患者的治疗效果。

下一代癌症诊断市场面临的限制因素

由于报销政策不明朗，下一代癌症诊断市场面临许多挑战，阻碍了创新技术的广泛应用。这种不确定性对医疗服务提供者和患者都带来了障碍，因为这使得证明先进诊断检测相关成本的合理性变得更加困难。各国、各地区和各医疗体系的报销政策差异进一步加剧了这个问题。许多此类政策仍不完善，难以就尖端诊断技术的合理报销方式达成共识。因此，经济因素可能会阻碍医疗服务提供者在临床实践中全面应用这些宝贵的工具，从而限制其对患者照护的潜在影响。

下一代癌症诊断市场趋势

下一代癌症诊断市场正经历着向液态生物检体检测的重大转变，液体活检检测因其革新癌症诊断和后续观察的潜力而日益受到认可。透过对血液和尿液等体液进行非侵入性分析，这些检测方法相比传统的组织切片检查，提供了更安全、更经济的选择。液体活检检测能够及时、准确地提供癌症的存在和进展信息，这推动了其在医疗服务提供者和患者中的快速普及。这也促使许多公司投入大量资金，致力于创新和提升液态生物检体技术的有效性，从而进一步推动了市场成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Roche Holding AG（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Illumina, Inc.（USA）
Abbott Laboratories（USA）
QIAGEN NV（Germany/Netherlands）
Agilent Technologies, Inc.（USA）
Bio-Rad Laboratories, Inc.（USA）
Becton, Dickinson and Company（BD）（USA）
Myriad Genetics, Inc.（USA）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
Danaher Corporation（USA）
Siemens Healthineers AG（Germany）
Hologic, Inc.（USA）
GE Healthcare（USA）
Novartis AG（Switzerland）
Merck KGaA（Germany）
Sysmex Corporation（Japan）
Invitae Corporation（USA）

结论与建议

简介目录

Product Code: SQMIG35A2226

Next Generation Cancer Diagnostics Market size was valued at USD 18.84 Billion in 2024 and is poised to grow from USD 22.33 Billion in 2025 to USD 86.81 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The market for next-generation cancer diagnostics is experiencing a transformative shift towards rapid point-of-care testing, driven by the commercialization of innovative diagnostic devices, kits, and reagents. This transition is anticipated to elevate market growth, particularly with the rise of companion diagnostics, which are becoming essential in delivering advanced, personalized genomic medicine. The increasing global incidence of various cancers underscores the urgency for sophisticated diagnostic tools that facilitate early detection and subsequently improve treatment outcomes. As new biomarkers are continually developed, the accuracy and cost-effectiveness of cancer diagnostics enhance. The focus on minimally invasive techniques further emphasizes the critical role of early detection in achieving favorable patient outcomes, addressing significant healthcare challenges associated with rising cancer mortality rates.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. This approach focuses on customizing treatments to suit individual patients, taking into account their unique genetic makeup and other specific features. Advanced diagnostic tools in this sector play a crucial role by identifying patients who are most likely to respond favorably to targeted therapies. As more healthcare professionals recognize the advantages of these tailor-made treatment strategies, the reliance on innovative diagnostic solutions intensifies, thereby propelling market growth and enhancing patient outcomes in cancer care.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges due to unclear reimbursement policies, which hinder the adoption of innovative technologies. This uncertainty creates obstacles for healthcare providers and patients, as justifying the costs associated with advanced diagnostic tests becomes complicated. Variability in reimbursement policies across different countries, regions, and healthcare systems further exacerbates the issue. Many of these policies remain underdeveloped, leading to a lack of consensus on appropriate reimbursement methods for these cutting-edge diagnostics. Consequently, the financial implications can deter healthcare providers from fully integrating these valuable tools into clinical practice, limiting their potential impact on patient care.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is witnessing a significant shift towards liquid biopsy tests, which are increasingly recognized for their potential to revolutionize cancer diagnosis and monitoring. By utilizing non-invasive methods to analyze bodily fluids such as blood and urine, these tests offer a safer, more cost-effective alternative to traditional tissue biopsies. Their ability to provide timely and precise insights into cancer presence and progression is driving their rapid adoption among healthcare providers and patients alike. Consequently, this trend has attracted substantial investments from companies aiming to innovate and enhance the efficacy of liquid biopsy technologies, further propelling market growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2026-2033)

Market Overview
Products
- Instruments
- Kits & consumables
Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

Market Overview
Next-generation sequencing (NGS)
Polymerase chain reaction (PCR)
DNA microarrays
Multiplexing
Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Cervical cancer
Liver cancer
Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

Market Overview
Screening and early detection
Prognostics and monitoring
Therapy selection
Recurrence monitoring
Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospitals & clinics
Diagnostic laboratories
Academic & research institutions
Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2026-2033)

North America (Product and Services, Technology, Cancer Type, Application, End Use)
- US
- Canada
Europe (Product and Services, Technology, Cancer Type, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany/Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments